{"title":"浙江省50岁成人带状疱疹疫苗接种的成本-效果分析","authors":"Fuxing Chen, Linglin Ding, Yu Hu","doi":"10.3389/fpubh.2025.1401930","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Live-attenuated zoster vaccine (LZV) and adjuvanted recombinant zoster vaccine (RZV) have been approved for use in China. This study aimed to evaluate and compare the cost-effectiveness of these two herpes zoster (HZ) vaccination strategies in a birth cohort of individuals aged 50 years.</p><p><strong>Methods: </strong>The cost-effectiveness of RZV and LZV was compared to no vaccination strategy using a lifetime Markov model from a societal perspective. Model parameters were obtained from up-to-date published literature and statistical data. The costs associated with vaccination and medical treatment, quality-adjusted life years (QALYs), the number of herpes zoster and related complication cases averted, and the incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed to assess the robustness of the results.</p><p><strong>Results: </strong>Compared to the no-vaccination strategy, the RZV strategy was estimated to prevent 4,126 HZ cases and 772 postherpetic neuralgia (PHN) cases, while the LZV strategy was estimated to avert 2,355 HZ cases and 467 PHN cases. The ICER was estimated at 711.46 US $/QALY and 914.62 US $/QALY for the RZV and LZV strategies, respectively.</p><p><strong>Conclusion: </strong>HZ vaccination could provide significant health benefits at a reasonable cost. RZV was predicted to be more cost-effective than LZV.</p>","PeriodicalId":12548,"journal":{"name":"Frontiers in Public Health","volume":"13 ","pages":"1401930"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106458/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50 years in Zhejiang province, China.\",\"authors\":\"Fuxing Chen, Linglin Ding, Yu Hu\",\"doi\":\"10.3389/fpubh.2025.1401930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Live-attenuated zoster vaccine (LZV) and adjuvanted recombinant zoster vaccine (RZV) have been approved for use in China. This study aimed to evaluate and compare the cost-effectiveness of these two herpes zoster (HZ) vaccination strategies in a birth cohort of individuals aged 50 years.</p><p><strong>Methods: </strong>The cost-effectiveness of RZV and LZV was compared to no vaccination strategy using a lifetime Markov model from a societal perspective. Model parameters were obtained from up-to-date published literature and statistical data. The costs associated with vaccination and medical treatment, quality-adjusted life years (QALYs), the number of herpes zoster and related complication cases averted, and the incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed to assess the robustness of the results.</p><p><strong>Results: </strong>Compared to the no-vaccination strategy, the RZV strategy was estimated to prevent 4,126 HZ cases and 772 postherpetic neuralgia (PHN) cases, while the LZV strategy was estimated to avert 2,355 HZ cases and 467 PHN cases. The ICER was estimated at 711.46 US $/QALY and 914.62 US $/QALY for the RZV and LZV strategies, respectively.</p><p><strong>Conclusion: </strong>HZ vaccination could provide significant health benefits at a reasonable cost. RZV was predicted to be more cost-effective than LZV.</p>\",\"PeriodicalId\":12548,\"journal\":{\"name\":\"Frontiers in Public Health\",\"volume\":\"13 \",\"pages\":\"1401930\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106458/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fpubh.2025.1401930\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fpubh.2025.1401930","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50 years in Zhejiang province, China.
Objective: Live-attenuated zoster vaccine (LZV) and adjuvanted recombinant zoster vaccine (RZV) have been approved for use in China. This study aimed to evaluate and compare the cost-effectiveness of these two herpes zoster (HZ) vaccination strategies in a birth cohort of individuals aged 50 years.
Methods: The cost-effectiveness of RZV and LZV was compared to no vaccination strategy using a lifetime Markov model from a societal perspective. Model parameters were obtained from up-to-date published literature and statistical data. The costs associated with vaccination and medical treatment, quality-adjusted life years (QALYs), the number of herpes zoster and related complication cases averted, and the incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed to assess the robustness of the results.
Results: Compared to the no-vaccination strategy, the RZV strategy was estimated to prevent 4,126 HZ cases and 772 postherpetic neuralgia (PHN) cases, while the LZV strategy was estimated to avert 2,355 HZ cases and 467 PHN cases. The ICER was estimated at 711.46 US $/QALY and 914.62 US $/QALY for the RZV and LZV strategies, respectively.
Conclusion: HZ vaccination could provide significant health benefits at a reasonable cost. RZV was predicted to be more cost-effective than LZV.
期刊介绍：
Frontiers in Public Health is a multidisciplinary open-access journal which publishes rigorously peer-reviewed research and is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians, policy makers and the public worldwide. The journal aims at overcoming current fragmentation in research and publication, promoting consistency in pursuing relevant scientific themes, and supporting finding dissemination and translation into practice.
Frontiers in Public Health is organized into Specialty Sections that cover different areas of research in the field. Please refer to the author guidelines for details on article types and the submission process.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
